Kiora Pharmaceuticals (KPRX) AI Stock Analysis

• Market Cap: $9.60M
• Dividend Yield: N/A
• Average Volume (3M): 9.44K
• Price to Earnings (P/E): 4.5
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): 0.71
• Shares Outstanding: 3,000,788
• 10 Day Avg. Volume: 5,974
• 30 Day Avg. Volume: 9,441
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.62
• Price to Cash Flow (P/CF): 2.70
• P/FCF Ratio: 2.70
• Enterprise Value/Market Cap: -1.75
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.05
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 212.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Kiora Pharmaceuticals shows strong financial health with solid revenue growth and minimal debt, contributing positively to its stock score. However, weak technical indicators suggest bearish market sentiment, partially offsetting the financial strengths. The attractive valuation with a low P/E ratio presents potential upside, particularly if technical conditions improve.

Positive Factors

Clinical Trials

The company has received approval to initiate the Phase 2 ABACUS-2 trial of KIO-301 in retinitis pigmentosa.

Financial Position

The company had $26.8M in cash and investments, which may be sufficient to fund operations into 2027.

Partnerships

Kiora has secured a partnership with Laboratoires Théa with a $16M upfront payment and potential milestones up to $285M, indicating strong commercial support.

Negative Factors

Clinical Risks

Risks include the failure of KIO-301 in clinical trials, to secure regulatory approval, or to achieve commercial success due to reimbursement, penetration rate, and competition.

Financial Performance

For 4Q24, net loss was $4.2M, higher than the estimated loss of $2.7M.

Kiora Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Kiora Pharmaceuticals generates revenue primarily through the sale and licensing of its ophthalmic products and therapies. The company's revenue model includes direct sales to healthcare providers, partnerships with pharmaceutical companies for the co-development and distribution of its products, and potential milestone payments and royalties from licensing agreements. These partnerships and collaborations are crucial as they provide access to broader markets and additional resources for research and development. Kiora's focus on innovative treatments for eye disorders positions it to capture a niche market, potentially leading to substantial revenue growth as its products gain regulatory approval and market acceptance.

Kiora Pharmaceuticals Financial Statement Overview

Summary

Kiora Pharmaceuticals has shown significant revenue growth in 2024 and improved profitability metrics, with a 100% gross profit margin and a net profit margin of 48.2%. The company maintains minimal leverage with a debt-to-equity ratio of 0.002 and a strong equity position. However, cash flow metrics suggest limited operational efficiency, though overall financial health remains promising.

Income Statement

Kiora Pharmaceuticals showed significant revenue growth in 2024 with a total revenue of $16.02 million compared to zero in previous years, indicating a positive turnaround. The gross profit margin is 100% for 2024, suggesting effective cost management. However, the net profit margin stands at 48.2%, hinting at some cost controls needing improvement. The EBIT margin is at 16.4%, but the absence of EBITDA data limits further analysis.

Balance Sheet

The balance sheet reveals a solid equity position with a debt-to-equity ratio of 0.002, indicating minimal leverage and strong financial stability. The return on equity is 30%, reflecting efficient use of equity to generate profits. The equity ratio is 70.6%, suggesting a healthy balance between debt and equity financing.

Cash Flow

The company experienced positive free cash flow in 2024, a substantial improvement from previous years. The free cash flow to net income ratio is 1.11, indicating strong cash generation relative to profits. However, the operating cash flow to net income ratio of 1.11 suggests that cash generation from operations aligns closely with net income, which may limit further cash flow leverage.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
16.02M	0.00	0.00	0.00	12.06K
	Gross Profit
16.02M	-4.03M	-134.03K	-227.27K	-188.16K
	EBIT
4.51M	-12.59M	-12.31M	-16.94M	-8.19M
	EBITDA
5.70M	-12.35M	-13.55M	-13.73M	-6.65M
	Net Income Common Stockholders
3.59M	-12.51M	-13.58M	-16.39M	-8.09M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
26.79M	2.45M	5.96M	7.85M	1.19M
	Total Assets
36.48M	13.71M	18.68M	18.06M	15.16M
	Total Debt
57.17K	106.89K	105.78K	209.41K	362.12K
	Net Debt
-3.74M	-2.35M	-5.86M	-7.65M	-823.56K
	Total Liabilities
10.72M	7.60M	7.27M	8.83M	8.16M
	Stockholders Equity
25.76M	6.11M	11.41M	9.22M	7.00M
Cash Flow		Free Cash Flow
8.55M	-9.56M	-10.43M	-10.95M	-7.45M
	Operating Cash Flow
8.56M	-9.56M	-10.43M	-10.89M	-7.32M
	Investing Cash Flow
-22.66M	0.00	6.38K	-157.02K	-244.44K
	Financing Cash Flow
15.50M	5.97M	8.62M	17.80M	5.00M

Kiora Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Neutral. The current price of 3.2 is above the 20-day moving average (MA) of 2.85, above the 50-day MA of 3.11, and below the 200-day MA of 3.52, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 62.38 is Neutral, neither overbought nor oversold. The STOCH value of 85.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KPRX.

Kiora Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPRX	56 Neutral	$9.60M	4.53	22.56%	―	―	―
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
NURO	43 Neutral	$8.94M	―	-45.38%	―	-48.61%	32.18%
LYRA	42 Neutral	$6.92M	―	-184.99%	―	-1.54%	-7.20%
ACXP	39 Underperform	$9.06M	―	-534.03%	―	―	23.65%

Kiora Pharmaceuticals Corporate Events

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.